Highway To FIM – How To Avoid
Roadblocks During Preclinical

Wednesday, July 26th, 10:00 – 15:00
IZB Residence Campus at Home (Am Klopferspitz 21, 82152 Planegg)


In early drug development, thorough understanding of drug metabolism and toxicology is essential for success. This knowledge helps us identify potential risks, design effective risk mitigation strategies, and accelerate the process of bringing safe and efficacious drugs to patients, improving their health and quality of life.

In this NUVISAN Lunch & Learn, our experts will share an overview and exclusive insight into the considerations and various tailor-made approaches to address these challenges during preclinical compound profiling and beyond.


10:00 – 10:30
Welcome Reception & Introduction

Dr. Stephanie Urschel (VP Business Development)
Dr. Alexander Aslanidis (Business Development Manager)
Dr. Michael Meyring (Head of PK Sciences)

10:30 – 11:10
Don’t let drug-drug-interactions be a blockade on your way to FIM

Dr. Dirk Scharn (Head of In Vitro PK)

11:10 – 11:50
Early human MetID – smooth the road to human mass balance

Dr. Matthias Bader (Head of Biotransformation)

12:00 – 13:00
Lunch at restaurant Seven & More sponsored by NUVISAN

13:10 – 13:50
Toxicology studies – how to get to FIM on the fast track

Dr. Burkhard Flick (Head of Toxicology)

13:50 – 15:00
Closing Remarks & QA


Stephanie Urschel

Dr. Stephanie Urschel

VP Business Development

Visit LinkedIn Profile

Dr. Alexander Aslanidis

Business Development Manager

Visit LinkedIn Profile

Dr. Michael Meyring

Head of PK Sciences

Dr. Dirk Scharn

Head of In Vitro PK

Dr. Matthias Bader

Head of Biotransformation

Dr. Burkhard Flick

Head of Toxicology